MedPath

Defining a novel law of glucose homeostasis under SGLT-2 inhibitor usage by mathematical model approch

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000020141
Lead Sponsor
Division of Diabetes and Endocrinology Department of Internal Medicine Kobe University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1) pregnant or breast-feeding 2) insulin antibody positive (>10 arbitrary unit ) 3) having allergy of skin trouble for oral hypoglycemic agants or insulin 4) type 1 diabetes or other specific type of diabetes 5) severe liver dysfunction (transaminase twice over the normal limit) 6) severe renal dysfunction (eGFR<50) 7) severe heart failure(NYHA>2) 8) long-acting insulin, long-acting GLP-1 RA, or long-acting DPP-4 inhibitor user 9) psychologic disorder 10) recent severe hypoglycemia or hypoglycemia unawareness 11) contraindication of dapagliflozin others inappropriate for this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath